Dominic Smethurst - 03 Jan 2023 Form 4 Insider Report for BICYCLE THERAPEUTICS plc (BCYC)

Reporting relationship: Chief Medical Officer
Issuer ticker: BCYC
Reported as of: 03 Jan 2023
Net transaction value: -$52,337
SEC form: 4
Accepted by SEC: 05 Jan 2023, 20:18:03 UTC
Prior SEC filing: 05 Jan 2022
Next SEC filing: 29 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Lee Kalowski, Attorney-in-Fact

Key filing fact

Dominic Smethurst filed Form 4 for BICYCLE THERAPEUTICS plc (BCYC) on 05 Jan 2023.

Key facts

This page summarizes Dominic Smethurst's Form 4 filing for BICYCLE THERAPEUTICS plc (BCYC).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2023, 20:18.

Change

Previous filing in this sequence was filed on 05 Jan 2022.
Current net transaction value: -$52,337.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCYC transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +17,500
Change %: +83%
Price: $0.000000
Shares after: 38,500
Date: 03 Jan 2023
Ownership: Direct
Footnotes: F1, F2

BCYC transaction

Ordinary Shares

Sale

Transaction value: $52,337
Shares: -1,801
Change %: -4.7%
Price: $29.06
Shares after: 36,699
Date: 03 Jan 2023
Ownership: Direct
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCYC transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +35,000
Change %
Price: $0.000000
Shares after: 35,000
Date: 03 Jan 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 35,000
Exercise price: $29.60
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

Footnote F2

Each RSU represents a contingent right to receive one ordinary share.

Footnote F3

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter.